JAN 28, 2021 6:00 AM PST

Killers With a Hit on the Spike

WRITTEN BY: Tara Fernandez

Natural killer cells, or NK cells, are specialized immune cells of the innate immune system. Their job revolves around eliminating the spread of cells that are either cancerous or that have been infected by pathogens. 

Certain cell therapy strategies aim to harness the power and potential of NK cells by genetically modifying them to target specific antigens. A recent study has demonstrated that one of these potential targets is the spike protein of the COVID-causing coronavirus, SARS-CoV-2. The research team that performed the work were from the Center for Immunity and Inflammation at the New Jersey Medical School.

For cell therapy applications, the modification of the cells involves the isolation of immune cells from the peripheral blood or bone marrow before genetically engineering them to express the chimeric antigen receptor or CAR. Approved cell therapies using CAR-T cells, mostly for cancer treatments, have not been the first choice as COVID therapies. In some patients, the administration of CAR-Ts can result in the side effect of raising systemic levels of cytokines in the body, similar to the “cytokine storm” caused by SARS-CoV-2 infections. CAR-NKs, however, are gentler and less likely to have these unwanted adverse effects.

In the study published in the bioRxiv preprint server, scientists developed NK cells that express CAR using the S309 antibody—an antibody isolated from individuals who had recovered from COVID infections, which showed high affinity for the spike protein of the virus, which upon binding, neutralizes it.

Why not just use the S309 antibody as a therapeutic? Because, say the authors, the half-life of monoclonal antibody therapies is only around three weeks. In contrast, these modified NK cells persist for much longer, forming a more potent and lasting shield against infection symptoms.

The next steps are to further validate S309-CAR-NK against full viral particles rather than the pseudotyped spike protein molecules used in the study. Testing in pre-clinical animal models will also help predict the potential efficacy of the new therapy in patients.

“These results pave the way for generating ‘off-the-shelf’ S309-CAR-NK cells for treatment in high-risk individuals as well as provide an alternative strategy for patients unresponsive to current vaccines,” wrote the authors in the manuscript.

 

 

Source: bioRxiv.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 29, 2021
Immunology
The Heartbreaking Nature of COVID Revealed
JUN 29, 2021
The Heartbreaking Nature of COVID Revealed
Researchers at the Washington University School are getting to the root of heart damage resulting from COVID-19 infectio ...
AUG 03, 2021
Immunology
Some Neutralizing Antibodies Make COVID Worse
AUG 03, 2021
Some Neutralizing Antibodies Make COVID Worse
Antibodies are specialized proteins produced as part of the body's immune response. Neutralizing antibodies bind to ...
AUG 07, 2021
Cancer
New Drug Combo Eliminates Pancreatic Cancer in Mice
AUG 07, 2021
New Drug Combo Eliminates Pancreatic Cancer in Mice
A combination of three immunotherapy drugs can eliminate pancreatic tumors in mice. The study was published in Canc ...
AUG 18, 2021
Neuroscience
Histamine Regulates Serotonin Levels in Depression
AUG 18, 2021
Histamine Regulates Serotonin Levels in Depression
Heightened histamine levels from inflammation inhibit the effects of the mood-regulating neurotransmitter serotonin in t ...
SEP 02, 2021
Immunology
Will an Extra COVID Vaccine Shot Benefit People With Autoimmune Conditions?
SEP 02, 2021
Will an Extra COVID Vaccine Shot Benefit People With Autoimmune Conditions?
The global rollout of COVID-19 vaccines has helped save countless lives during the pandemic. Studies have shown that vac ...
SEP 03, 2021
Cell & Molecular Biology
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
SEP 03, 2021
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
Scientists have sought to learn more about why some people get severe COVID-19 while others have only mild cases. We kno ...
Loading Comments...